{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=19", "query": { "intervention": "Control Capsules", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 2901, "total_pages": 291, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T12:09:48.208Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01619683", "title": "Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Effect of Treatment on Bone Mineral Density" ], "interventions": [ { "name": "enclomiphene citrate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repros Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "MALE", "summary": "18 Years to 60 Years · Male only" }, "enrollment_count": 300, "start_date": "2012-09", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2014-10-01", "last_synced_at": "2026-10-24T12:09:48.208Z", "location_count": 17, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 14 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01619683" }, { "nct_id": "NCT02924727", "title": "Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myocardial Infarction" ], "interventions": [ { "name": "LCZ696 (sacubitril/valsartan)", "type": "DRUG" }, { "name": "Ramipril", "type": "DRUG" }, { "name": "Placebo of LCZ696", "type": "DRUG" }, { "name": "Placebo of ramipril", "type": "DRUG" }, { "name": "Valsartan", "type": "DRUG" }, { "name": "Placebo of valsartan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5669, "start_date": "2016-12-09", "completion_date": "2021-02-26", "has_results": true, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-24T12:09:48.208Z", "location_count": 81, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02924727" }, { "nct_id": "NCT06247488", "title": "Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Abuse Potential" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Oxycodone 20 mg", "type": "DRUG" }, { "name": "GE-IR 200 mg", "type": "DRUG" }, { "name": "GE-IR 450 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arbor Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 110, "start_date": "2022-01-31", "completion_date": "2023-04-25", "has_results": true, "last_update_posted_date": "2024-08-12", "last_synced_at": "2026-10-24T12:09:48.208Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06247488" }, { "nct_id": "NCT01809327", "title": "A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canagliflozin 100 mg", "type": "DRUG" }, { "name": "Canagliflozin 300 mg", "type": "DRUG" }, { "name": "Metformin XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1186, "start_date": "2013-06-04", "completion_date": "2014-12-02", "has_results": true, "last_update_posted_date": "2017-07-11", "last_synced_at": "2026-10-24T12:09:48.208Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01809327" }, { "nct_id": "NCT01412060", "title": "A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Cariprazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 765, "start_date": "2011-09-27", "completion_date": "2014-09-03", "has_results": true, "last_update_posted_date": "2018-07-06", "last_synced_at": "2026-10-24T12:09:48.208Z", "location_count": 25, "location_summary": "Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01412060" }, { "nct_id": "NCT00294723", "title": "To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "liraglutide", "type": "DRUG" }, { "name": "glimepiride", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 746, "start_date": "2006-02", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-10-24T12:09:48.208Z", "location_count": 102, "location_summary": "Concord, California • Escondido, California • Fullerton, California + 83 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "Mission Viejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00294723" }, { "nct_id": "NCT00676403", "title": "Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Restless Legs Syndrome" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "Pregabalin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 137, "start_date": "2008-04", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2021-02-10", "last_synced_at": "2026-10-24T12:09:48.208Z", "location_count": 15, "location_summary": "Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 12 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00676403" }, { "nct_id": "NCT03247556", "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ADHD" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "400mg SPN-812", "type": "DRUG" }, { "name": "600mg SPN-812", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 297, "start_date": "2017-11-20", "completion_date": "2019-02-14", "has_results": true, "last_update_posted_date": "2021-07-02", "last_synced_at": "2026-10-24T12:09:48.208Z", "location_count": 14, "location_summary": "Long Beach, California • Colorado Springs, Colorado • Bradenton, Florida + 9 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Lauderhill", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03247556" }, { "nct_id": "NCT01191086", "title": "Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "USL255", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Upsher-Smith Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 210, "start_date": "2010-10", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-02-23", "last_synced_at": "2026-10-24T12:09:48.208Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Ventura, California • Gainsville, Florida + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Ventura", "state": "California" }, { "city": "Gainsville", "state": "Florida" }, { "city": "Gulf Breeze", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01191086" }, { "nct_id": "NCT04658186", "title": "A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early-stage Parkinson's Disease" ], "interventions": [ { "name": "UCB0599", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 496, "start_date": "2020-12-30", "completion_date": "2024-09-06", "has_results": true, "last_update_posted_date": "2025-10-31", "last_synced_at": "2026-10-24T12:09:48.208Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04658186" } ] }